How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Buy
54
PTGX Quote, Financials, Valuation and Earnings
Last price:
$48.35
Seasonality move
:
13.71%
Day range:
$47.09 - $48.80
52-week range:
$24.22 - $60.60
Dividend yield:
0%
P/E ratio:
11.64x
P/S ratio:
7.12x
P/B ratio:
4.44x
Volume:
664.5K
Avg. volume:
1.4M
1-year change:
68.96%
Market cap:
$3B
Revenue:
$434.4M
EPS (TTM):
$4.20
Protagonist Therapeutics SEC Filings
| Company | Filed | Form Type | Description | |
|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics
|
11/02/2023 | 10-Q | 10-Q filing on 11/02/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/03/2023 | 10-Q | 10-Q filing on 08/03/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/04/2023 | 10-Q | 10-Q filing on 05/04/2023 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/08/2022 | 10-Q | 10-Q filing on 11/08/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/04/2022 | 10-Q | 10-Q filing on 08/04/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/05/2022 | 10-Q | 10-Q filing on 05/05/2022 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/03/2021 | 10-Q | 10-Q filing on 11/03/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/04/2021 | 10-Q | 10-Q filing on 08/04/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/04/2021 | 10-Q | 10-Q filing on 05/04/2021 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/04/2020 | 10-Q | 10-Q filing on 11/04/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/06/2020 | 10-Q | 10-Q filing on 08/06/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/07/2020 | 10-Q | 10-Q filing on 05/07/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/10/2020 | 10-K | 10-K filing on 03/10/2020 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/06/2019 | 10-Q | 10-Q filing on 11/06/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/07/2019 | 10-Q | 10-Q filing on 08/07/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/08/2019 | 10-Q | 10-Q filing on 05/08/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/12/2019 | 10-K | 10-K filing on 03/12/2019 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/06/2018 | 10-Q | 10-Q filing on 11/06/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/07/2018 | 10-Q | 10-Q filing on 08/07/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/09/2018 | 10-Q | 10-Q filing on 05/09/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/07/2018 | 10-K | 10-K filing on 03/07/2018 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/07/2017 | 10-Q | 10-Q filing on 11/07/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
08/08/2017 | 10-Q | 10-Q filing on 08/08/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
05/10/2017 | 10-Q | 10-Q filing on 05/10/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
03/07/2017 | 10-K | 10-K filing on 03/07/2017 | View Form |
|
PTGX
Protagonist Therapeutics
|
11/14/2016 | 10-Q | 10-Q filing on 11/14/2016 | View Form |
|
PTGX
Protagonist Therapeutics
|
09/15/2016 | 10-Q | 10-Q filing on 09/15/2016 | View Form |
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is up 109.21% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 14.4% over the past day.
